Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DCLK1 siRNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
DCLK1 siRNA is an experimental small interfering RNA (siRNA) designed to silence the expression of the Doublecortin-Like Kinase 1 (DCLK1) gene through RNA interference. DCLK1 is a serine/threonine kinase that serves as a marker for tumor stem cells and is overexpressed in various malignancies, including colorectal, pancreatic, and renal cell cancers, as well as in fibrotic conditions like idiopathic pulmonary fibrosis (IPF). In preclinical models, knockdown of DCLK1 using siRNA has been shown to inhibit epithelial-mesenchymal transition (EMT), reduce cancer stem cell markers, decrease tumor cell invasion and migration, and sensitize cells to chemotherapy and radiation. In the context of pulmonary fibrosis, DCLK1 siRNA attenuates fibroblast activation, myofibroblast transformation, and extracellular matrix production. It is primarily used as a research tool in academic laboratories and has been evaluated in various delivery systems, such as liposomes and PLGA nanoparticles.
- Other names
- Doublecortin-like kinase 1 siRNAsiDCLK1siDCLK-1siDCLK 1
02
Targets
DCLK1 (Doublecortin-like kinase 1)
Beyond the preview
Go deeper on DCLK1 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DCLK1 siRNA.